The Signal Transducer IL6ST (gp130) as a Predictive and Prognostic Biomarker in Breast Cancer

Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer

(2021) Argun Akcakanat et al.   CLINICAL CANCER RESEARCH

A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors

(2020) Sukhvir Kaur et al.   BIOORGANIC & MEDICINAL CHEMISTRY

GP130 Cytokines in Breast Cancer and Bone

(2020) Tolu Omokehinde et al.   Cancers

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

(2020) K. Almstedt et al.   BREAST CANCER RESEARCH AND TREATMENT

Identification of Modulated MicroRNAs Associated with Breast Cancer, Diet, and Physical Activity

(2020) Luca Falzone et al.   Cancers

The impact of EndoPredict ® on decision making with increasing oncological work experience: can overtreatment be avoided?

(2019) Fabinshy Thangarajah et al.   ARCHIVES OF GYNECOLOGY AND OBSTETRICS

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone

(2019) Ivana Sestak et al.   BREAST CANCER RESEARCH AND TREATMENT

Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only

(2019) Martin Filipits et al.   CLINICAL CANCER RESEARCH

Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines

(2019) Masaaki Murakami et al.   IMMUNITY

Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study

(2019) Daniel Herr et al.   PLoS One

The Regulatory Role of MicroRNAs in Breast Cancer

(2019) Hui-Yi Loh et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

MicroRNAs in breast cancer: Roles, functions, and mechanism of actions

(2019) Maryam Abolghasemi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Construction of a novel multi-gene assay (42-gene classifier) for prediction of late recurrence in ER-positive breast cancer patients

(2018) Ryo Tsunashima et al.   BREAST CANCER RESEARCH AND TREATMENT

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

(2018) Daniel E. Johnson et al.   Nature Reviews Clinical Oncology

The role of the interleukin (IL)-6/IL-6 receptor axis in cancer

(2018) Mustafa Yassin Taher et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer

(2018) Ali Masjedi et al.   BIOMEDICINE & PHARMACOTHERAPY

The evolving role of receptors as predictive biomarkers for metastatic breast cancer

(2018) Carlos Martínez-Pérez et al.   Expert Review of Anticancer Therapy

Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)

(2017) M.J. Duffy et al.   EUROPEAN JOURNAL OF CANCER

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

(2017) Ian Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

(2017) Hongchao Pan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of genes and pathways related to lymphovascular invasion in breast cancer patients: A bioinformatics analysis of gene expression profiles

(2017) Sukhontip Klahan et al.   TUMOR BIOLOGY

Interleukin-6 Family Cytokines

(2017) Stefan Rose-John   Cold Spring Harbor Perspectives in Biology

Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer

(2017) Tomas Reinert et al.   Frontiers in Oncology

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy

(2016) Richard Buus et al.   JNCI-Journal of the National Cancer Institute

Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer

(2016) Tae-Hwe Heo et al.   Oncotarget

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy

(2016) Richard Buus et al.   JNCI-Journal of the National Cancer Institute

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) E. Senkus et al.   ANNALS OF ONCOLOGY

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial

(2015) F Fitzal et al.   BRITISH JOURNAL OF CANCER

Emerging roles for IL-11 signaling in cancer development and progression: Focus on breast cancer

(2015) Cameron N. Johnstone et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer

(2015) Arran K. Turnbull et al.   JOURNAL OF CLINICAL ONCOLOGY

Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer

(2015) Yingbo Shao et al.   PLoS One

Analysis of gene expression of secreted factors associated with breast cancer metastases in breast cancer subtypes

(2015) Elana J. Fertig et al.   Scientific Reports

Novel genes associated with lymph node metastasis in triple negative breast cancer

(2015) Andrea Mathe et al.   Scientific Reports

Gender-associated expression of tumor markers and a small gene set in breast carcinoma

(2014) Sarah A. Andres et al.   BREAST

The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer

(2014) Martin Filipits et al.   CLINICAL CANCER RESEARCH

Construction of novel immune-related signature for prediction of pathological complete response to neoadjuvant chemotherapy in human breast cancer

(2013) Y. Sota et al.   ANNALS OF ONCOLOGY

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients

(2013) P Dubsky et al.   BRITISH JOURNAL OF CANCER

Breast Cancer Index Identifies Early-Stage Estrogen Receptor-Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence

(2013) Y. Zhang et al.   CLINICAL CANCER RESEARCH

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population

(2013) Dennis C Sgroi et al.   LANCET ONCOLOGY

The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions

(2013) Berit Maria Müller et al.   PLoS One

Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test

(2012) Ralf Kronenwett et al.   BMC CANCER

Decentral gene expression analysis for ER+/Her2− breast cancer: results of a proficiency testing program for the EndoPredict assay

(2012) Carsten Denkert et al.   VIRCHOWS ARCHIV

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

(2011) Martin Filipits et al.   CLINICAL CANCER RESEARCH

gp130 at the nexus of inflammation, autoimmunity, and cancer

(2010) J. S. Silver et al.   JOURNAL OF LEUKOCYTE BIOLOGY

What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer?

(2009) C. H. Barrios et al.   ANNALS OF ONCOLOGY

OSM, LIF, Its Receptors, and Its Relationship with the Malignance in Human Breast Carcinoma (In Situand in Infiltrative)

(2008) Ignacio García-Tuñón et al.   CANCER INVESTIGATION